Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Judge Issues CMO For Testosterone Lawsuits Alleging Heart Attacks and Strokes Caused By "Low T" Drugs Such As Androgel
  • USA - English


News provided by

Wright & Schulte LLC

Sep 22, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Judge In Testosterone Lawsuit Claims Issues Case Management Order
Judge In Testosterone Lawsuit Claims Issues Case Management Order

If your believe you have suffered cardiovascular problems due to Androgel, Testim, Androderm or other Testosterone Therapy Drugs Call Wright & Schulte today for a Free Legal Evaluation at 1-800-399-0795 or by visiting www.yourlegalhelp.com

Post this

Columbus, OH (PRWEB) September 22, 2014 -- A Case Management Order (CMO) was issued on August 25, 2014, to set up the discovery phase for testosterone lawsuit claims pending in multidistrict litigation in the U.S. District Court, Northern District of Illinois. Wright & Schulte LLC notes the CMO, parties involved have until mid October to submit initial disclosures about potential witnesses and documents in testosterone therapy lawsuits. The order further instructed attorneys to continue negotiating the topics in Plaintiff Fact Sheets before another status conference is held for the testosterone treatment litigation. The CMO also directed the parties to discuss coordination with state courts over testosterone lawsuit filings. The testosterone lawsuits filed in state and federal courts against manufacturers of testosterone treatment medications such as Androgel, Androderm and Axiron, allege that men have suffered deep vein thrombosis, pulmonary embolism, heart attacks, strokes and death allegedly from taking testosterone treatment medication. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

Multidistrict litigation for the testosterone complaints was created in June by a panel of federal judges at the request of plaintiffs was sought a consolidation of all testosterone lawsuits filed in federal courts across the country. The judicial panel granted the request by transferring 45 testosterone complaints that were pending in four different federal courts across the country to the federal court in Northern Illinois. Court records for MDL 2545 show that the initial number of 45 lawsuits has more than tripled to 177 testosterone replacement therapy lawsuits pending litigation, as of August 15, 2014. The low testosterone treatment lawsuits are filed against various companies that manufacture and market testosterone replacement therapy products.
[jpml.uscourts.gov/sites/jpml/files/MDL-2545-Initial_Transfer-05-14.pdf, June 6, 2014]
[jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-August-15-2014.pdf, August 15, 2014]

Wright & Schulte LLC notes that court records show testosterone therapy lawsuits have been mounting since the U.S. Food & Drug Administration (FDA) announced in January that it was investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products for hypoganadism, which is low testosterone levels in men due to an underlying medical condition. As part of its ongoing reassessment of low testosterone replacement drugs, the FDA is convening a meeting of two of its advisory committees on September 17 and 18. The The Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee are scheduled to discuss issues surrounding testosterone treatment, such as what is the appropriate patient population for testosterone replacement therapy, and the potential risk of major cardiovascular events associated with using testosterone medication.
[fda.gov/Drugs/DrugSafety/ucm383904.htm, January 31, 2014] [fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM412536.pdf, August 22, 2014]

The FDA said it decided to re-evaluate the safety and effectiveness of testosterone products after reviewing two observational studies. A study published in the November 2013 Journal of the American Medical Association found that older men who had underlying cardiovascular disease and took low testosterone treatment had a 30 percent increased risk of having a stroke, heart attack or death compared to men who did not take the low testosterone medication. The second study reviewed by the FDA was published in the PLOS One Journal in January 2014. This study found that men over 65 and younger men with a pre-existing heart disease were at a greater risk of having a heart attack within the first 90 days after taking low testosterone drugs for the first time.
[plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085805, January 29, 2014] [jama.jamanetwork.com/article.aspx?articleid=1764051, November 6, 2013]

According to court records, a testosterone replacement therapy lawsuit was filed on September 3, 2014, in the U.S. District Court, Northern District of Illinois on behalf of a Colorado man who had a heart attack allegedly after using testosterone treatment therapy. (Case: 1:14-cv-06795) The complaint named as defendants, AbbVie Inc., and Abbott Laboratories, which manufactures and markets AndroGel; and Eli Lilly and Company, which manufactures and markets Axiron. According to the lawsuit, the Colorado man began taking Axiron in March 2013 after his doctor prescribed the testosterone medication to him. The next month, the man switched to taking AndroGel after his urologist prescribed this testosterone medication. The man continued to use AndroGel through June 2013. The testosterone lawsuit states that the man was hospitalized from June 15 to June 17, 2013 where he was diagnosed with a myocardial infarction (heart attack). The testosterone complaint alleges that the man’s myocardial infarction was due to his use of AndroGel and Axiron. The complaint contends that the man continues to suffer physical impairment, requires medical monitoring relating to his injuries, and has other problems related to his injury. The lawsuit accuses the defendants of failing to adequately warn consumers and their health care providers about the cardiovascular risks of using testosterone medications, including AndroGel and Axiron. The testosterone complaint stated that had the man and his doctors knew about the true risks associated with testosterone medication use, he would not have taken AndroGel and Axiron, and would have been adequately monitored for the side-effects of the testosterone medications.

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free low testosterone lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Richard Schulte, Wright & Schulte LLC, http://yourlegalhelp.com/, +1 1-800-399-0795, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.